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ABSTRACT
Introduction: Worldwide, suboptimal immunisation
coverage causes the deaths of more than one million
children under five from vaccine-preventable diseases
every year. Reasons for suboptimal coverage are
multifactorial, and a combination of interventions is
needed to improve compliance with immunisation
schedules. One intervention relies on reminders,
where the health system prompts caregivers to attend
immunisation appointments on time or re-engages
caregivers who have defaulted on scheduled
appointments. We undertake this systematic review
to investigate the potential of reminders using
emails, phone calls, social media, letters or postcards
to improve immunisation coverage in children
under five.
Methods and analysis: We will search for
published and unpublished randomised controlled
trials and non-randomised controlled trials in
PubMed, Scopus, CINAHL, CENTRAL, Science Citation
Index, WHOLIS, Clinicaltrials.gov and the WHO
International Clinical Trials Platform. We will conduct
screening of search results, study selection, data
extraction and risk-of-bias assessment in duplicate,
resolving disagreements by consensus. In addition,
we will pool data from clinically homogeneous studies
using random-effects meta-analysis; assess
heterogeneity of effects using the χ2 test of
homogeneity; and quantify any observed heterogeneity
using the I2 statistic.
Ethics and dissemination: This protocol does not
need approval by an ethics committee because we will
use publicly available data, without directly involving
human participants. The results will provide updated
evidence on the effects of electronic and postal
reminders on immunisation coverage, and we will
discuss the applicability of the findings to low and
middle-income countries. We plan to disseminate
review findings through publication in a peer-reviewed
journal and presentation at relevant conferences.
In addition, we will prepare a policymaker-friendly
summary using a validated format (eg, SUPPORT
Summary) and disseminate this through social media
and email discussion groups.
Review registration number: PROSPERO
registration number CRD42014012888.
INTRODUCTION
Immunisation is a healthcare process in
which an individual gains immunity or resist-
ance to a disease through administration of a
vaccine.1 Immunisation is important in all
stages of an individual’s life as it helps chil-
dren and adolescents ﬁght infectious diseases
and restores waning immunity in adults.2
Besides beneﬁts to the individual who
receives the vaccine, immunisation helps
protect his or her family members, friends
and the community at large.3 The WHO esti-
mates that immunisation currently averts 2–3
million deaths every year in all age groups.
These are deaths that would have been
caused by diphtheria, tetanus, whooping
cough (pertussis), measles and other
vaccine-preventable diseases.4
Strengths and limitations of this study
▪ This protocol complies with the PRISMA-P
guidelines.
▪ We will employ the Grading of
Recommendations Assessment, Development
and Evaluation approach to establish the cer-
tainty of the evidence on the effectiveness of
reminders in improving childhood immunisation
coverage.
▪ Non-randomised controlled trials are eligible for
inclusion in this review. This study design tends
to have a high risk of selection bias, but we plan
to alleviate this risk by conducting sensitivity
analyses to evaluate the robustness of the evi-
dence to risk of bias by excluding studies with a
high risk of selection bias.
▪ We anticipate a wide clinical variation across
studies relating to participants, study settings
and country income levels. We will mitigate the
impact of such heterogeneity on the validity of
our findings by pooling data only from clinically
homogeneous studies.
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The percentage of people who receive one or more
vaccines of interest in relation to the target population is
referred to as vaccination coverage. The vaccination
coverage by 1 year of age for the third dose of a vaccine
containing diphtheria, tetanus and pertussis (DTP3) is
regarded as a proxy for childhood immunisation cover-
age worldwide.5 Low childhood immunisation coverage
is a signiﬁcant public health issue, with great implication
on children’s health.6 The WHO estimates that DTP3
coverage increased from 76% in 1990 to 86% in 2014
worldwide.4 However, the increase in immunisation
coverage is uneven; in 2014, DTP3 coverage was 96% in
Europe and the Western Paciﬁc and only 77% in Africa.
The estimated number of children under 1 year of age
who did not receive DTP3 was 18.7 million worldwide in
2014, with more than three-ﬁfths of them residing in 10
low and middle-income countries: the Democratic
Republic of Congo, Ethiopia, India, Indonesia, Iraq,
Nigeria, Pakistan, the Philippines, Uganda and South
Africa.4 As a consequence of low immunisation coverage,
1.5 million children continue to die from vaccine-
preventable diseases worldwide yearly.7
Immunisation coverage is affected by factors related
to the health system, healthcare workers and caregivers
(ie, parents or other persons assuming the parental
role).8–10 Caregiver factors that inﬂuence childhood
immunisation coverage include (but are not limited to)
low socioeconomic status, low parental education,
younger maternal age, lack of knowledge about the
importance of immunisation, negative attitudes towards
immunisation, fear of side effects and forgetting vaccin-
ation schedules and appointments.9 10
In line with the optimisation of childhood immunisa-
tion coverage, policymakers and healthcare workers
need to put in place purposeful, structured, repeatable
and adaptable approaches to sustain high immunisation
coverage during childhood, irrespective of who the chil-
dren are or where they live.11 A potentially important
strategy for achieving and sustaining high childhood
immunisation coverage involves communicating the
dates of scheduled vaccination visits and details of the
vaccines on schedule to caregivers as well as re-engaging
those caregivers who have missed vaccination appoint-
ments to bring their children to receive the vaccines
due.12–15
Various systematic reviews have assessed the effective-
ness of such reminder methods in improving childhood
immunisation coverage, and we summarise the most
relevant ones below.13–16 Williams et al13 conducted a sys-
tematic search and found 46 eligible studies published
between 1980 and 2009 on strategies to optimise immun-
isation coverage among children under ﬁve in devel-
oped countries. Twenty-two studies focused on
reminders to advise parents of upcoming vaccinations
that are due and remind parents of those children who
are overdue. The reminders ranged from automated
telephone calls and generic postcards to personalised
letters and home visits. There was heterogeneity of
effects between types of reminders, with an overall effect
being a median point change in coverage of +11%
(range −11% to +24%). However, these data were col-
lected six or more years ago and may not be applicable
to low and middle-income countries where most unim-
munised children live.
In another review, Oyo-Ita and coauthors assessed
the effectiveness of intervention strategies to boost and
sustain high-childhood immunisation coverage in low
and middle-income countries.14 The authors included
six studies published between 1996 and 2009, but
excluded studies focusing on reminder and recall
methods because they were included in an existing
review.15 The latter assessed the effectiveness of patient
reminder and recall systems in improving immunisation
coverage, and compared the effects of various types of
reminders in different patient populations. The authors
included 47 studies available by May 2007 involving par-
ticipants of all ages, and found that caregiver remin-
ders improved childhood immunisation coverage: OR
1.47, 95% CIs 1.28 to 1.68). The review focused on
high-income countries where (potential) recipients of
care have primary healthcare providers whom they visit
regularly.15 Thus, the ﬁndings of the review would not
be directly applicable to low and middle-income
countries.
More recently, Harvey et al16 conducted a systematic
review and meta-analysis of parental interventions to
improve early childhood (0–5 years) vaccine uptake.
The authors conducted six pooled analyses involving 28
studies, and report that all interventions were somehow
effective, although the effects were inconsistent, with a
combination of postal and telephone reminders being
the most effective reminder method: risk difference
0.1132, 95% CI 0.033 to 0.193. However, the authors
excluded studies that did not provide outcome data in
terms of the number of children completely immunised
or up-to-date for their age from meta-analyses. In add-
ition, interventions for which only one study was found
were excluded from pooled analyses. Overall, included
studies of reminder interventions in the analyses were
published in 2011 or earlier.16 The review therefore pro-
vides very low-certainty evidence on the effects of newer
methods of reminders on childhood immunisation
coverage. Recognising this limitation, the authors indi-
cate that strategies used in most included studies may
not be relevant to caregivers of today.
It would therefore be prudent to conduct a new sys-
tematic review that includes the newer methods of
reminders such as text messages, twitter and other forms
of social media. In addition, Harvey et al did not use
Grading of Recommendations Assessment, Development
and Evaluation (GRADE)17 or a similar approach to
assess the certainty of the evidence on the effectiveness
of reminder methods in improving childhood immunisa-
tion coverage. We propose to ﬁll this evidence gap by
conducting a systematic review that will include all
methods of sending reminders, and use the GRADE
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system to establish the certainty of the evidence and
present the data in ‘Summary of Findings’ tables.18 In
addition, we will use a validated format to summarise
the review ﬁndings for non-research end users, includ-
ing (but not limited to) healthcare workers, programme
managers and policymakers
OBJECTIVES
Our objective is to assess the effects of caregiver remin-
ders on the uptake of the WHO-recommended vaccines
in children less than 5 years of age.
METHODS AND ANALYSIS
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs,
deﬁned as studies in which participants were allocated
to interventions at random) and non-randomised con-
trolled trials (Non-RCTs, deﬁned as trials that allocated
participants to treatment arms by a non-random method
such as alternation between groups and the use of birth-
dates or weekdays). We will include RCT and non-RCT
trials with allocation at both individual and cluster levels.
For trials with allocation at the cluster level, we will only
include those with at least two intervention and two
control clusters.
Types of participants
The participants of interest for this review will be care-
givers (ie, parents or other persons fulﬁlling the paren-
tal role) of children in need of the WHO-recommended
vaccines.
Types of interventions
Eligible interventions will be electronic mail (emails,
text messages, twitter, other forms of social media, tele-
phone calls) or postal mail (letters or postcards) deliv-
ered to caregivers to remind them of scheduled
vaccination visits for their children or recall those who
have missed vaccination visits. We will include multifa-
ceted interventions involving any of the eligible interven-
tions and conduct a subgroup analysis by nature of
interventions (single or multifaceted). Eligible compari-
sons include no intervention, standard immunisation
practices in the given setting, other interventions, or the
same interventions delivered at a different level of inten-
sity. Interventions meant only to inform or educate care-
givers about the importance of vaccination are outside
the scope of this review and will be excluded. In add-
ition, we will exclude studies focusing on reminders for
providers (rather than recipients) of care.
Types of outcome measures
The primary outcome for this review is vaccination
coverage in children under ﬁve (as deﬁned by the
authors). Childhood vaccination coverage can be
reported in a variety of ways, including coverage with
individual vaccines, uptake of a combination of vaccines,
DTP3 coverage, the proportion of fully immunised chil-
dren and the percentage of children up-to-date with
recommended vaccines.6 14–16 We will include studies
with all these outcomes. The secondary outcomes will be
the cost of the intervention, the incidence of vaccine-
preventable diseases, the acceptability of the interven-
tion, adverse events following immunisation and undesir-
able effects of the interventions.
Search methods for identification of studies
We have developed a comprehensive search strategy for
peer-reviewed literature (see online supplementary
appendix). Searches will be conducted in PubMed,
Scopus, Cochrane Central Register of Controlled Trials
(CENTRAL), ISI Web of Science (Science Citation
Index), Cumulative Index of Nursing and Allied Health
(CINAHL) and PDQ Evidence. We will also check refer-
ence lists of relevant reviews and full-text articles
assessed for eligibility in this review. In addition, we will
search the WHO International Clinical Trials Registry
Platform and Clinicaltrials.gov for ongoing trials.
Data collection and analysis
Selection of studies
Two review authors (MC and VM) will independently
screen the search outputs for potentially eligible studies.
We will obtain the full text of studies deemed potentially
eligible by at least one of the two authors, and the two
authors will independently assess them for eligibility
against the study inclusion criteria (ie, types of studies,
participants, interventions and outcomes). We will
endeavour to obtain English translations for eligible arti-
cles published in languages other than English.
Data extraction and management
We will use the Cochrane Collaboration’s Review
Manager (RevMan: http://ims.cochrane.org/RevMan)
for data management and statistical analyses. The two
authors will use a predesigned pilot-tested data collec-
tion form to independently extract data on study design
and methods, country setting (including income level as
deﬁned by the World Bank),19 participant character-
istics, intervention characteristics, study outcomes and
study funding sources.
Assessment of risk of bias in included studies
Risk of bias in included studies will be assessed inde-
pendently by MC and VM, using the Cochrane Risk of
Bias tool.20 The following domains will be assessed:
random sequence generation, allocation concealment,
blinding of participants and personnel, blinding of
outcome assessors, completeness of outcome data, com-
pleteness of outcome reporting and other potential
sources of bias (eg, baseline imbalance and conﬂicts of
interest). Judgements will be made for each domain as
low risk of bias, unclear risk of bias or high risk of bias
according to the criteria in the Cochrane handbook.
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For cluster-randomised controlled trials, we will include
additional domains for assessment such as ‘loss of clus-
ters’. We will categorise each included study into one of
three levels of bias: low, moderate and high risk of bias.
Studies classiﬁed as low risk of bias for all domains will
be considered to be at low risk of bias. Studies with a
high risk of selection, detection or attrition bias will be
categorised as having high risk of bias. All other studies
will be considered to have moderate risk of bias.
Resolving discrepancies following duplicate assessments
The two authors (MC and VM) conducting independent
screening of search outputs, assessment of study eligibil-
ity, extraction of data from included studies and assess-
ment of risk of bias in eligible studies will compare their
results after each stage and resolve any differences by
discussion and consensus. Should there be no consensus
between the two, a third author (FM or CSW) will
arbitrate.
Measures of effect
We will express study results for binary data as risk ratios
and 95% CIs. For cost of interventions, we will report
the costs in the currencies provided by the trial authors,
with the current US$ equivalents. Where the data are
reported as a small number of ordinal categories, these
data will be converted to binary data. For example, in
the event that the acceptability of interventions is
categorised as acceptable, moderately acceptable and
not acceptable, the groups will be converted into two
groups: acceptable (acceptable or moderately accept-
able) versus not acceptable. For continuous data,
such as the incidence of vaccine-preventable diseases,
we will calculate unadjusted mean differences (MD)
with their SDs.
Data synthesis
We will use both ﬁxed-effect and random-effects
methods to pool data from clinically homogeneous
studies, and compare the results to assess the impact of
statistical heterogeneity. We will then present the results
from the random-effects method, unless it is contraindi-
cated (eg, if there is funnel plot asymmetry). In the
presence of funnel plot asymmetry, we will present
the estimates of effects from both methods of
meta-analyses, with the assumption that funnel plot
asymmetry indicates that neither method is more
appropriate. If both show a presence (or absence) of
effect, we will be reassured; if they do not agree, we will
report this. We will include data from eligible cluster
RCTs in relevant meta-analyses after controlling for the
design effect, using the intracluster correlation coefﬁ-
cient (ICC).
We will calculate overall intervention effects using
generic inverse variance20 and use the GRADE approach
to categorise the certainty of the evidence for the effect
of each intervention on each outcome as high, moder-
ate, low or very low.17
Unit of analysis issues
We expect that controlled trials which allocated partici-
pants at cluster levels will appropriately control for clus-
tering. However, if such data are instead reported as if
allocation to interventions was performed at the level of
the individual, we will request individual participant data
to use in estimating the ICC. If individual participant
data are not available, we will obtain external ICC esti-
mates from external sources and use them to re-analyse
the data.20
Dealing with missing data
We will contact the authors of included studies to supply
relevant unreported data on our primary outcomes. For
studies reporting outcomes only for participants who
completed the trial or followed the protocol, we will
request the additional information that would permit us
to conduct intention-to-treat analyses. Should we not
receive any requested missing data, we will describe the
missing data and discuss the extent to which the missing
data could alter our results. We will conduct sensitivity
analyses to assess the impacts of missing data on esti-
mates of effect.
Assessment of heterogeneity
We will assess clinical variation across studies by compar-
ing the distribution of important characteristics relating
to participants (eg, age), study settings (eg, single or
sample of medical practice or clinic settings) and
country income level according to the World (high,
middle or low). We will pool data from clinically homo-
geneous studies, examine statistical heterogeneity
between study results using the χ2 test of homogeneity
(with signiﬁcance deﬁned at the α level of 10%), and
describe any observed statistical heterogeneity between
study results using the I2 statistic.20
Assessment of reporting biases
Should we include 10 or more studies in a meta-analysis,
we will use funnel plots to assess the possibility of publi-
cation bias because when there are fewer studies, funnel
plot asymmetry tests are not a reliable means of differen-
tiating true asymmetry from the play of chance.21
Funnel plot asymmetry can emanate from real inconsist-
ency of effects of interventions; publication and other
biases (eg, selective outcome reporting), poor methodo-
logical quality (poor methodological design, inadequate
analysis, fraud) or chance.22
Subgroup analysis
We will carry out subgroup analyses for the primary
outcome (vaccination coverage), with subgroups deﬁned
by intervention subtype (emails, telephone calls, text
messaging, twitter, letters and postcards), nature of inter-
vention (single or multifaceted intervention), country
income level as deﬁned by the World Bank (high-
income, middle-income and low-income countries)19
and study design (RCTs and non-RCTs). Where
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appropriate, the intention-to-treat principle and the
available case principle will be used to analyse the data.
Sensitivity analysis
We will conduct sensitivity analyses to investigate the
robustness of the results to risk of bias (low vs high risk
of bias). For sensitivity analyses, we will deﬁne ‘high risk
of bias’ based on each of three criteria, namely inad-
equate concealment of intervention allocation, inad-
equate blinding of outcome assessment and substantial
loss to follow-up and/or withdrawals from allocated
interventions. If we include cluster-randomised trials
and insufﬁcient information is available to adjust for
clustering, we will use individuals as the unit of analysis
and perform sensitivity analyses to assess the potential
bias that may have occurred as a result of inadequately
controlling for the effects of clustering. We will also
perform sensitivity analyses if ICCs were obtained from
external sources.
Reporting of the review findings
We have written this protocol and will report the review
ﬁndings as recommended by relevant PRISMA guide-
lines.23–25 In addition, we will present the outputs of our
data analysis in forest plots and GRADE summary of
ﬁndings tables.18
Ethics and dissemination
The review protocol does not need approval by an ethics
committee because we will use publicly available data
without directly involving human participants. We pub-
lished an outline of the protocol26 in the PROSPERO
International Prospective Register of Systematic Reviews
in 2014, registration number: CRD42014012888. The
results will provide updated evidence on the effects of
electronic and postal reminders on immunisation cover-
age, and we will discuss the applicability of the ﬁndings
to low and middle-income countries. We plan to dissem-
inate review ﬁndings through publication in a peer-
reviewed journal and present at relevant scientiﬁc con-
ferences. In addition, we will prepare a policymaker-
friendly summary using a validated format (eg,
SUPPORT Summary)27 and disseminate this through
social media and email discussion groups.
Twitter Follow Charles Wiysonge at @CharlesShey
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